Cited by 27Virus-based gene therapy researchMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune Responses

Engineering humoral immunity as prophylaxis or therapy

Open access
Deal, Cailin E, Balazs, Alejandro B·2015·Current Opinion in Immunology

Abstract

Purpose of the review In this review, we will discuss the field of engineered humoral immunity with an emphasis on recent work using viral vectors to produce antibodies in vivo. As an alternative to passive transfer of monoclonal antibody protein, a transgene encoding an antibody is delivered to cells via vector transduction, resulting in expression and secretion by the host cell. This review will summarize the evidence in support of this strategy as an alternative to traditional vaccines against infection and as novel therapeutics for a variety of diseases.Recent findings Historically, humoral immunity has been engineered through vaccination and passive transfer of monoclonal antibodies. However, recent work suggests that vectors can be used to deliver transgenes encoding broadly neutralizing antibodies to non-hematopoietic tissues and can mediate long-term expression that is capable of preventing or treating infectious diseases. The production of engineered monoclonal antibodies allows for precise targeting and elimination of aberrant self-proteins that are characteristic of certain neurodegenerative disease. This approach has also been successfully used to combat cancer and addiction in several animal models. Despite the wide array of expression platforms that have been described, adeno-associated virus vectors have emerged as the frontrunner for rapid clinical translation.Summary Recent advances in vector-mediated antibody expression have demonstrated the potential for such interventions to prevent infection and treat disease. As such, it offers an alternative to immunogen-based vaccine design and a novel therapeutic intervention by enabling precise manipulation of humoral immunity. Success translating these approaches to patients may enable the development of effective prevention against previously intractable pathogens that evade immunity such as HIV, influenza, malaria or HCV and may also enable new treatment options for neurodegenerative diseases such as Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.coi.2015.06.014

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For safety reasons, transient vectors or regulated expression would be preferred for clinical use.

    “for safety reasons, transient vectors or regulated expression would be preferred for clinical use (Deal & Balazs, 2015).”

    From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Deal & Balazs, 2015

    The “Vectored Antibody Delivery for Cancer” section (page unavailable) says clinical translation of vectored antibody delivery for cancer will require transient vectors or regulated mAb delivery. The claim extends that recommendation to clinical use generally and gives safety as the reason, which the passage does not explicitly state. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 61 · Cited by 27

Authors
Deal, C. E., & Balazs, A. B.
Affiliations
Ragon Institute of MGH, MIT and Harvard (US)
Corresponding author
Balazs, Alejandro B
Venue
Current Opinion in Immunology
Publisher
Elsevier BV
Published
2015-08
Volume
35
Pages
113-122
ISSN
0952-7915 (ISSN-L)
OpenAlex
W910576623
Cited by
27
References
61
Citations by year
2025: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 1 · 2015: 1
FWCI
0.51
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Allergy and Infectious Disease
  • National Institutes for Drug Abuse
  • William F. Milton Fund
  • Charles H. Hood Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
viral vectors, adeno-associated virus vectors, broadly neutralizing antibodies, passive antibody transfer, vaccine alternatives, cancer immunotherapy, addiction treatment, neurodegenerative diseases, Alzheimer's disease, HIV, influenza, malaria, hepatitis C virus
MeSH terms
Animals, Genetic Vectors, Humans, Immunotherapy, Infections, Vaccines, Protein Engineering, Transgenes, Immunity, Humoral, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review